Denileukin Diftitox: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Denileukin Diftitox. Educational only — not medical advice.
Labeled uses
LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Source: FDA labeling via NIH DailyMed (set ac3613d7…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.